Gefarnate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Gefarnate
Skeletal formula
Space-filling model
Systematic (IUPAC) name
(2E)-3,7-dimethylocta-2,6-dien-1-yl (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate
Clinical data
AHFS/Drugs.com International Drug Names
Legal status ?
Identifiers
CAS number 51-77-4 YesY
ATC code A02BX07
PubChem CID 5282182
ChemSpider 4445377 N
UNII 1ISE2Y6ULA YesY
KEGG D01529 YesY
Chemical data
Formula C27H44O2 
Mol. mass 400.637 g/mol
 N (what is this?)  (verify)

Gefarnate is a drug used for the treatment of gastric ulcers.[1]

It also has been proposed for use in the treatment of dry eye syndrome.[2][3]

References[edit]

  1. ^ Ohta Y, Kobayashi T, Imai Y, Inui K, Yoshino J, Nakazawa S (August 2005). "Effect of gefarnate on acute gastric mucosal lesion progression in rats treated with compound 48/80, a mast cell degranulator, in comparison with that of teprenone" ([dead link]Scholar search). Biol. Pharm. Bull. 28 (8): 1424–30. doi:10.1248/bpb.28.1424. PMID 16079487. 
  2. ^ Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J (April 2008). "Therapeutic targets in dry eye syndrome". Drug News Perspect. 21 (3): 166–76. PMID 18560615. 
  3. ^ Gipson IK, Hori Y, Argüeso P (April 2004). "Character of ocular surface mucins and their alteration in dry eye disease". Ocul Surf 2 (2): 131–48. PMID 17216084.